Company Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.
It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.
Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| IPO Date | Dec 5, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,543 |
| CEO | John Charles Jacobs M.B.A. |
Contact Details
Address: 21 Firstfield Road Gaithersburg, Maryland United States | |
| Website | https://www.novavax.com |
Stock Details
| Ticker Symbol | NVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000694 |
| CUSIP Number | 670002401 |
| ISIN Number | US6700024010 |
| Employer ID | 22-2816046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Charles Jacobs M.B.A. | President, Chief Executive Officer & Director |
| James Patrick Kelly C.F.A. | Executive Vice President, Chief Financial Officer & Treasurer |
| John Joseph Trizzino B.S., M.B.A. | President & Chief Operating Officer |
| Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Richard P. Crowley | Executive Vice President & Chief Operating Officer |
| Dr. Robert Walker M.D. | Senior Vice President & Chief Medical Officer |
| Erika S. Trahan | Associate Director of Investor & Public Relations |
| Ian J. Watkins | Executive Vice President & Chief Human Resources Officer |
| Silvia Taylor M.B.A. | Executive Vice President and Chief Corporate Affairs & Advocacy Officer |
| Troy Morgan Esq., J.D. | Senior Vice President, Deputy General Counsel & Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 4 | Filing |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 3 | Filing |